JP2011068653A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011068653A5 JP2011068653A5 JP2010237937A JP2010237937A JP2011068653A5 JP 2011068653 A5 JP2011068653 A5 JP 2011068653A5 JP 2010237937 A JP2010237937 A JP 2010237937A JP 2010237937 A JP2010237937 A JP 2010237937A JP 2011068653 A5 JP2011068653 A5 JP 2011068653A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- administered
- composition according
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 9
- 230000037396 body weight Effects 0.000 claims 8
- 239000002552 dosage form Substances 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 3
- 239000006187 pill Substances 0.000 claims 3
- 239000003826 tablet Substances 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- VONIYVYPMHRCOX-UHFFFAOYSA-N CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)O)N1c(cc1)cc(F)c1C(NC)=O Chemical compound CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)O)N1c(cc1)cc(F)c1C(NC)=O VONIYVYPMHRCOX-UHFFFAOYSA-N 0.000 description 1
- NMWKXPOYFABJRA-UHFFFAOYSA-N CNC(c(c(F)c1)ccc1N(C1(CCCC1)C(N1c(cc2)cc(C(F)(F)F)c2C#N)=O)C1=S)=O Chemical compound CNC(c(c(F)c1)ccc1N(C1(CCCC1)C(N1c(cc2)cc(C(F)(F)F)c2C#N)=O)C1=S)=O NMWKXPOYFABJRA-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68083505P | 2005-05-13 | 2005-05-13 | |
| US60/680,835 | 2005-05-13 | ||
| US75035105P | 2005-12-15 | 2005-12-15 | |
| US60/750,351 | 2005-12-15 | ||
| US75655206P | 2006-01-06 | 2006-01-06 | |
| US60/756,552 | 2006-01-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008511114A Division JP4644737B2 (ja) | 2005-05-13 | 2006-03-29 | ジアリールヒダントイン化合物 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012168905A Division JP2012211190A (ja) | 2005-05-13 | 2012-07-30 | ジアリールヒダントイン化合物 |
| JP2012168904A Division JP5150780B2 (ja) | 2005-05-13 | 2012-07-30 | ジアリールヒダントイン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011068653A JP2011068653A (ja) | 2011-04-07 |
| JP2011068653A5 true JP2011068653A5 (enExample) | 2012-09-13 |
| JP5138753B2 JP5138753B2 (ja) | 2013-02-06 |
Family
ID=37431537
Family Applications (13)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008511114A Active JP4644737B2 (ja) | 2005-05-13 | 2006-03-29 | ジアリールヒダントイン化合物 |
| JP2010237937A Active JP5138753B2 (ja) | 2005-05-13 | 2010-10-22 | ジアリールヒダントイン化合物 |
| JP2012168905A Withdrawn JP2012211190A (ja) | 2005-05-13 | 2012-07-30 | ジアリールヒダントイン化合物 |
| JP2012168904A Active JP5150780B2 (ja) | 2005-05-13 | 2012-07-30 | ジアリールヒダントイン化合物 |
| JP2015039980A Active JP6013535B2 (ja) | 2005-05-13 | 2015-03-02 | ジアリールヒダントイン化合物 |
| JP2016148183A Withdrawn JP2016183200A (ja) | 2005-05-13 | 2016-07-28 | ジアリールヒダントイン化合物 |
| JP2018039424A Withdrawn JP2018100292A (ja) | 2005-05-13 | 2018-03-06 | ジアリールヒダントイン化合物 |
| JP2019134558A Pending JP2019218352A (ja) | 2005-05-13 | 2019-07-22 | ジアリールヒダントイン化合物 |
| JP2020187901A Withdrawn JP2021035970A (ja) | 2005-05-13 | 2020-11-11 | ジアリールヒダントイン化合物 |
| JP2022071531A Pending JP2022101657A (ja) | 2005-05-13 | 2022-04-25 | ジアリールヒダントイン化合物 |
| JP2023043191A Pending JP2023075313A (ja) | 2005-05-13 | 2023-03-17 | ジアリールヒダントイン化合物 |
| JP2024115820A Pending JP2024153705A (ja) | 2005-05-13 | 2024-07-19 | ジアリールヒダントイン化合物 |
| JP2025134786A Pending JP2025166151A (ja) | 2005-05-13 | 2025-08-13 | ジアリールヒダントイン化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008511114A Active JP4644737B2 (ja) | 2005-05-13 | 2006-03-29 | ジアリールヒダントイン化合物 |
Family Applications After (11)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012168905A Withdrawn JP2012211190A (ja) | 2005-05-13 | 2012-07-30 | ジアリールヒダントイン化合物 |
| JP2012168904A Active JP5150780B2 (ja) | 2005-05-13 | 2012-07-30 | ジアリールヒダントイン化合物 |
| JP2015039980A Active JP6013535B2 (ja) | 2005-05-13 | 2015-03-02 | ジアリールヒダントイン化合物 |
| JP2016148183A Withdrawn JP2016183200A (ja) | 2005-05-13 | 2016-07-28 | ジアリールヒダントイン化合物 |
| JP2018039424A Withdrawn JP2018100292A (ja) | 2005-05-13 | 2018-03-06 | ジアリールヒダントイン化合物 |
| JP2019134558A Pending JP2019218352A (ja) | 2005-05-13 | 2019-07-22 | ジアリールヒダントイン化合物 |
| JP2020187901A Withdrawn JP2021035970A (ja) | 2005-05-13 | 2020-11-11 | ジアリールヒダントイン化合物 |
| JP2022071531A Pending JP2022101657A (ja) | 2005-05-13 | 2022-04-25 | ジアリールヒダントイン化合物 |
| JP2023043191A Pending JP2023075313A (ja) | 2005-05-13 | 2023-03-17 | ジアリールヒダントイン化合物 |
| JP2024115820A Pending JP2024153705A (ja) | 2005-05-13 | 2024-07-19 | ジアリールヒダントイン化合物 |
| JP2025134786A Pending JP2025166151A (ja) | 2005-05-13 | 2025-08-13 | ジアリールヒダントイン化合物 |
Country Status (29)
| Country | Link |
|---|---|
| EP (5) | EP3106162A1 (enExample) |
| JP (13) | JP4644737B2 (enExample) |
| KR (12) | KR101431407B1 (enExample) |
| CN (6) | CN102584712A (enExample) |
| AT (1) | ATE541571T1 (enExample) |
| AU (1) | AU2006248109B2 (enExample) |
| BE (1) | BE2013C074I2 (enExample) |
| BR (1) | BRPI0610359B8 (enExample) |
| CA (1) | CA2608436C (enExample) |
| CY (2) | CY1112798T1 (enExample) |
| DK (2) | DK2444085T3 (enExample) |
| ES (2) | ES2535179T3 (enExample) |
| HK (1) | HK1217103A1 (enExample) |
| HR (2) | HRP20120323T4 (enExample) |
| HU (1) | HUS1300076I1 (enExample) |
| IL (4) | IL187328A (enExample) |
| LU (1) | LU92338I2 (enExample) |
| ME (1) | ME01992B (enExample) |
| MX (4) | MX2007014132A (enExample) |
| NO (4) | NO339997B1 (enExample) |
| NZ (3) | NZ591119A (enExample) |
| PL (2) | PL1893196T5 (enExample) |
| PT (2) | PT1893196E (enExample) |
| RS (2) | RS52274B2 (enExample) |
| RU (3) | RU2448096C3 (enExample) |
| SG (1) | SG10201703816SA (enExample) |
| SI (2) | SI1893196T2 (enExample) |
| WO (1) | WO2006124118A1 (enExample) |
| ZA (2) | ZA200710870B (enExample) |
Families Citing this family (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004031881D1 (de) | 2003-12-19 | 2011-04-28 | Univ California | Verfahren und materialien zur beurteilung von prostatakrebstherapien |
| US7718684B2 (en) | 2004-02-24 | 2010-05-18 | The Regents Of The University Of California | Methods and materials for assessing prostate cancer therapies and compounds |
| EP3106162A1 (en) * | 2005-05-13 | 2016-12-21 | The Regents of the University of California | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| EP2656842B1 (en) * | 2006-03-27 | 2016-08-10 | The Regents of The University of California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
| WO2007127010A2 (en) * | 2006-03-29 | 2007-11-08 | The Regents Of The University Of California | Diarylthiohydantoin compounds |
| WO2008093838A1 (ja) * | 2007-02-01 | 2008-08-07 | Chugai Seiyaku Kabushiki Kaisha | スルファモイル基を有するピリジルイミダゾリジン誘導体、およびその医薬としての使用 |
| US8461343B2 (en) | 2007-03-27 | 2013-06-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
| CA2966280A1 (en) | 2007-10-26 | 2009-04-30 | The Regents Of The University Of California | Diarylhydantoin compounds |
| MX2011008858A (es) * | 2009-02-24 | 2012-01-27 | Medivation Prostate Therapeutics Inc | Compuestos de diarilhidantoina y diariltiohidantoina especificos. |
| CN101817787B (zh) * | 2009-02-26 | 2013-07-24 | 童友之 | 抗前列腺癌的雄性激素受体拮抗剂 |
| ES2707598T3 (es) * | 2009-05-12 | 2019-04-04 | Koninklijke Philips Nv | Fosfodiesterasa 4D7 como marcador para cáncer maligno de próstata sensible a hormonas |
| JP5659232B2 (ja) * | 2009-09-10 | 2015-01-28 | トン、ヨウヂ | アンドロゲン受容体アンタゴニストおよびその使用 |
| US20120238533A1 (en) | 2009-09-11 | 2012-09-20 | Bayer Pharma Aktiengesellschaft | (Heteroarylmethyl) Thiohydantoins as anticancer drugs |
| TW201111378A (en) | 2009-09-11 | 2011-04-01 | Bayer Schering Pharma Ag | Substituted (heteroarylmethyl) thiohydantoins |
| AR078793A1 (es) | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| US8722695B2 (en) | 2009-12-11 | 2014-05-13 | Autifony Therapeutics Limited | Imidazolidinedione derivatives |
| HUE037389T2 (hu) | 2010-02-16 | 2018-08-28 | Aragon Pharmaceuticals Inc | Androgén receptor modulátorok és alkalmazásaik |
| ES2671343T3 (es) | 2010-02-24 | 2018-06-06 | Medivation Prostate Therapeutics Llc | Procesos para la síntesis de compuestos de diariltiohidantoína y diarilhidantoína |
| RU2434851C1 (ru) | 2010-07-22 | 2011-11-27 | Александр Васильевич Иващенко | Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения |
| DK2649066T3 (en) | 2010-12-06 | 2016-01-11 | Autifony Therapeutics Ltd | Hydantoin derivatives using as KV3 inhibitors. |
| WO2012119559A1 (en) | 2011-03-10 | 2012-09-13 | Suzhou Kintor Pharmaceuticals,Inc. | Androgen receptor antagonists and uses thereof |
| US8921378B2 (en) | 2011-04-21 | 2014-12-30 | Orion Corporation | Androgen receptor modulating carboxamides |
| US9193704B2 (en) | 2011-06-07 | 2015-11-24 | Autifony Therapeutics Limited | Hydantoin derivatives as KV3 inhibitors |
| DK2739153T3 (en) | 2011-07-29 | 2018-12-03 | Medivation Prostate Therapeutics Llc | TREATMENT OF BREAST CANCER |
| CA2856646C (en) | 2011-11-30 | 2020-01-14 | Astrazeneca Ab | Combination treatment of cancer |
| CN103159680A (zh) * | 2011-12-14 | 2013-06-19 | 爱美尼迪药物有限公司 | 咪唑二酮类化合物及其用途 |
| AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
| BR112014028718A2 (pt) | 2012-05-22 | 2017-06-27 | Autifony Therapeutics Ltd | derivados de hidantoína como inibidores de kv3 |
| CN104334547B (zh) | 2012-05-22 | 2017-06-06 | 奥蒂福尼疗法有限公司 | 作为kv3抑制剂的三唑类 |
| JP6262733B2 (ja) * | 2012-09-04 | 2018-01-17 | シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | イミダゾリン誘導体、その製造法、およびそれらの医薬への適用 |
| BR112015005404A2 (pt) * | 2012-09-11 | 2017-08-22 | Dr Reddys Laboratories Ltd | Formas polimórficas de enzalutamida e sua preparação |
| EP4450130A3 (en) * | 2012-09-11 | 2025-01-08 | Medivation Prostate Therapeutics LLC | Formulations of enzalutamide |
| ES2836424T3 (es) | 2012-09-26 | 2021-06-25 | Aragon Pharmaceuticals Inc | Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración |
| US9944607B2 (en) | 2012-10-16 | 2018-04-17 | Whitehead Institute For Biomedical Research | Thiohydantoin derivatives and uses thereof |
| AU2013334102B2 (en) | 2012-10-26 | 2018-08-16 | Memorial Sloan-Kettering Cancer Center | Modulators of resistant androgen receptor |
| CA3105575A1 (en) | 2013-01-15 | 2014-07-24 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulator and uses thereof |
| RU2520134C1 (ru) * | 2013-02-27 | 2014-06-20 | Общество с ограниченной ответственностью "Авионко" (ООО "Авионко") | Замещенные (r)-3-(4-метилкарбамоил-3-фторфениламино)-тетрагидро-фуран-3-енкарбоновые кислоты и их эфиры, способ их получения и применения |
| WO2014167428A2 (en) * | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| JP2016526538A (ja) | 2013-06-20 | 2016-09-05 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 殺ダニ剤及び殺虫剤としてのアリールスルフィド誘導体及びアリールスルホキシド誘導体 |
| WO2015018356A1 (zh) * | 2013-08-08 | 2015-02-12 | 上海医药集团股份有限公司 | 二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用 |
| WO2015042170A1 (en) | 2013-09-17 | 2015-03-26 | Wayne State University | Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds |
| CA2921156A1 (en) * | 2013-09-19 | 2015-03-26 | Glaxosmithkline Llc | Combination drug therapy |
| CN106543085A (zh) * | 2013-10-14 | 2017-03-29 | 杭州普晒医药科技有限公司 | 恩杂鲁胺的固态形式及其制备方法和用途 |
| WO2015063720A1 (en) | 2013-10-31 | 2015-05-07 | Ranbaxy Laboratories Limited | Process for the preparation of enzalutamide |
| US20160318875A1 (en) | 2013-12-16 | 2016-11-03 | Sun Pharmaceutical Industries Limited | Processes and intermediates for the preparation of enzalutamide |
| US9682960B2 (en) | 2013-12-19 | 2017-06-20 | Endorecherche, Inc. | Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety |
| CN104803919A (zh) * | 2014-01-26 | 2015-07-29 | 上海医药工业研究院 | 用于制备恩杂鲁胺中间体的方法 |
| WO2015121768A1 (en) | 2014-02-13 | 2015-08-20 | Ranbaxy Laboratories Limited | Process for the preparation of enzalutamide |
| CZ2014232A3 (cs) | 2014-04-07 | 2015-10-14 | Zentiva, K.S. | Způsob výroby enzalutamidu |
| CN103896847B (zh) * | 2014-04-09 | 2016-01-20 | 沈江 | 一种非甾体类抗雄激素化合物及其制备方法和应用 |
| CN103910679B (zh) * | 2014-04-23 | 2016-05-25 | 杭州新博思生物医药有限公司 | 一种恩杂鲁胺的制备方法 |
| CN104003939B (zh) * | 2014-06-06 | 2017-07-07 | 山东大学 | 二芳基取代乙内酰硫脲类化合物及其制备方法与应用 |
| CN104016924B (zh) * | 2014-06-16 | 2016-04-13 | 上海鼎雅药物化学科技有限公司 | 一种“一锅法”合成恩杂鲁胺的方法 |
| WO2015196144A2 (en) | 2014-06-20 | 2015-12-23 | England Pamela M | Androgen receptor antagonists |
| RU2557235C1 (ru) * | 2014-07-08 | 2015-07-20 | Александр Васильевич Иващенко | Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты |
| EP3166931A4 (en) * | 2014-07-11 | 2018-05-09 | Shilpa Medicare Limited | An improved process for the preparation of enzalutamide |
| RS66323B1 (sr) | 2014-12-05 | 2025-01-31 | Aragon Pharmaceuticals Inc | Sastavi protiv raka |
| SG11201704425TA (en) | 2014-12-12 | 2017-06-29 | Medivation Prostate Therapeutics Inc | Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer |
| CN104610111A (zh) * | 2014-12-26 | 2015-05-13 | 杭州和泽医药科技有限公司 | 一种4-异硫代氰酰基-2-(三氟甲基)苯甲腈的制备方法 |
| CN105523958B (zh) * | 2015-01-13 | 2017-11-03 | 北京海步医药科技股份有限公司 | 一种制备二芳基硫代乙内酰脲衍生物关键中间体的方法 |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| MX390189B (es) * | 2015-01-20 | 2025-03-20 | Arvinas Operations Inc | COMPUESTOS Y METODOS PARA LA DEGRADACION DIRIGIDA DE RECEPTOR DE ANDROGENOs. |
| CN106187905B (zh) * | 2015-05-05 | 2020-02-21 | 北京海步医药科技股份有限公司 | 丁鲁他胺的结晶形式及其制备方法 |
| ITUB20151204A1 (it) | 2015-05-28 | 2016-11-28 | Olon Spa | Procedimento per la preparazione di enzalutamide |
| ITUB20151311A1 (it) * | 2015-05-28 | 2016-11-28 | Olon Spa | Procedimento per la preparazione di enzalutamide |
| ITUB20151256A1 (it) | 2015-05-28 | 2016-11-28 | Olon Spa | Processo industriale per la preparazione di enzalutamide |
| CN107635969B (zh) | 2015-05-29 | 2021-08-17 | 安斯泰来制药有限公司 | 恩杂鲁胺结晶形式的制造方法 |
| US10150739B2 (en) * | 2015-09-10 | 2018-12-11 | Jiangsu Hengrui Medicine Co., Ltd. | Crystalline form of androgen receptor inhibitor and preparation method thereof |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| WO2018009694A1 (en) * | 2016-07-08 | 2018-01-11 | Janssen Pharmaceutica Nv | Thiohydantoin androgen receptor antagonists for the treatment of cancer |
| KR20220028178A (ko) | 2016-12-16 | 2022-03-08 | 강푸 바이오파마슈티칼즈 리미티드 | 조성물, 이의 적용 및 치료 방법 |
| ES3018265T3 (en) | 2017-04-28 | 2025-05-14 | Astellas Pharma Inc | Orally administrable enzalutamide-containing pharmaceutical composition |
| UA129105C2 (uk) | 2017-10-16 | 2025-01-15 | Арагон Фармасьютикалз, Інк. | Антиандрогени для лікування неметастатичного резистентного до кастрації раку передміхурової залози |
| US10513504B2 (en) | 2018-03-08 | 2019-12-24 | Apotex Inc. | Processes for the preparation of apalutamide and intermediates thereof |
| CZ2018234A3 (cs) | 2018-05-21 | 2019-12-04 | Zentiva Ks | Zvýšení rozpustnosti a biodostupnosti enzalutamidu |
| CN108976171B (zh) * | 2018-08-27 | 2020-06-16 | 长沙泽达医药科技有限公司 | 化合物、组合物及其在药物制备中的用途 |
| WO2020095183A1 (en) | 2018-11-05 | 2020-05-14 | Pfizer Inc. | Combination for treating cancer |
| EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| US11292782B2 (en) | 2018-11-30 | 2022-04-05 | Nuvation Bio Inc. | Diarylhydantoin compounds and methods of use thereof |
| CN109796437B (zh) * | 2019-02-26 | 2021-08-24 | 上海健康医学院 | 具有ar和hdac双重抑制作用的乙内酰脲类和乙内酰硫脲类化合物及用途 |
| WO2020260469A1 (en) | 2019-06-27 | 2020-12-30 | Synthon B.V. | Process for preparation of enzalutamide |
| CN110452166A (zh) * | 2019-09-06 | 2019-11-15 | 浙江朗华制药有限公司 | 一种5-异硫氰酰基-3-三氟甲基-2-氰基吡啶的制备方法 |
| CA3152909A1 (en) | 2019-10-03 | 2021-04-08 | Synthon Bv | Pharmaceutical composition comprising enzalutamide |
| WO2021240206A1 (en) | 2020-05-24 | 2021-12-02 | Lotus International Pte. Ltd. | Enzalutamide formulation |
| JP2023537595A (ja) | 2020-08-13 | 2023-09-04 | ファイザー・インク | 併用治療 |
| MX2023006911A (es) | 2020-12-11 | 2023-06-26 | Ildong Pharmaceutical Co Ltd | Nuevos compuestos como inhibidor dual del receptor de androgenos y de la fosfodiesterasa. |
| MX2023011294A (es) | 2021-03-24 | 2023-10-05 | Pfizer | Combinacion de talazoparib y un antiandrogeno para el tratamiento del cancer de prostata sensible a la castracion metastasico mutado en el gen ddr. |
| EP4112603A1 (en) | 2021-06-29 | 2023-01-04 | Química Sintética, S.A. | Processes for the preparation of non-steroidal antiandrogens |
| KR102861133B1 (ko) | 2021-10-13 | 2025-09-16 | 주식회사 엘지에너지솔루션 | 배터리 충방전 프로파일 분석 방법 및 배터리 충방전 프로파일 분석 장치 |
| CN114181155A (zh) * | 2021-12-21 | 2022-03-15 | 上海朝晖药业有限公司 | 碘-恩杂鲁胺及其制备方法及其应用 |
| CN117164520B (zh) * | 2022-01-28 | 2025-04-25 | 南京思聚生物医药有限公司 | 一种局部作用的雄激素受体拮抗剂及其应用 |
| KR20230170859A (ko) | 2022-06-11 | 2023-12-19 | 이태영 | 패스트칫솔 |
| CN117327019A (zh) * | 2022-06-23 | 2024-01-02 | 南京思聚生物医药有限公司 | 一种局部作用的雄激素受体拮抗剂的应用 |
| TWI883565B (zh) | 2022-10-02 | 2025-05-11 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| EP4374853A1 (en) | 2022-11-22 | 2024-05-29 | Lotus Pharmaceutical Co., Ltd. | Solid formulation of enzalutamide |
| TW202425976A (zh) | 2022-12-17 | 2024-07-01 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| CN115850186B (zh) * | 2023-02-07 | 2024-04-09 | 长沙泽达医药科技有限公司 | 一种乙撑硫脲衍生物的晶型及用途 |
| WO2025125565A1 (en) | 2023-12-13 | 2025-06-19 | Krka, D.D., Novo Mesto | Tablet comprising enzalutamide |
| WO2025210510A1 (en) | 2024-04-04 | 2025-10-09 | Pfizer Inc. | Tmprss2-erg and rb1 as predictive biomarkers for treatment with a parp inhibitor |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2329276A1 (fr) | 1975-10-29 | 1977-05-27 | Roussel Uclaf | Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant |
| SU1380610A3 (ru) * | 1982-12-06 | 1988-03-07 | Пфайзер Инк. (Фирма) | Способ получени спирогетероазолидиндионов или их фармацевтически приемлемых солей |
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US5411981A (en) | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
| FR2693461B1 (fr) * | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| FR2671348B1 (fr) | 1991-01-09 | 1993-03-26 | Roussel Uclaf | Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant. |
| FR2694290B1 (fr) * | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| FR2715402B1 (fr) * | 1994-01-05 | 1996-10-04 | Roussel Uclaf | Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| EP0748220A4 (en) † | 1994-01-21 | 1997-09-10 | Sepracor Inc | METHOD AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R - (-) CASODEX |
| FR2725206B1 (fr) | 1994-09-29 | 1996-12-06 | Roussel Uclaf | Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant |
| US5656651A (en) | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
| FR2741342B1 (fr) * | 1995-11-22 | 1998-02-06 | Roussel Uclaf | Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques |
| US6673799B1 (en) | 1998-09-22 | 2004-01-06 | Yamanouchi Pharmaceutical Co. Ltd. | Cyanophenyl derivative |
| FR2796945B1 (fr) * | 1999-07-30 | 2002-06-28 | Sod Conseils Rech Applic | Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments |
| US6861432B2 (en) | 2001-11-23 | 2005-03-01 | Schering Aktiengesellschaft | Piperazine derivatives that destabilize androgen receptors |
| CA2500977A1 (en) | 2002-10-04 | 2004-04-15 | Laboratoires Fournier S.A. | 2-thiohydantoine derivative compounds and use thereof in therapeutics |
| FR2850652B1 (fr) | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| US20050005529A1 (en) | 2003-07-10 | 2005-01-13 | David Brault | Lighting system for a greenhouse |
| US7718684B2 (en) * | 2004-02-24 | 2010-05-18 | The Regents Of The University Of California | Methods and materials for assessing prostate cancer therapies and compounds |
| AU2005280908A1 (en) * | 2004-09-09 | 2006-03-16 | Chugai Seiyaku Kabushiki Kaisha | Novel imidazolidine derivative and use thereof |
| EP3106162A1 (en) * | 2005-05-13 | 2016-12-21 | The Regents of the University of California | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
-
2006
- 2006-03-29 EP EP16171151.0A patent/EP3106162A1/en not_active Withdrawn
- 2006-03-29 AT AT06748863T patent/ATE541571T1/de active
- 2006-03-29 KR KR1020137012351A patent/KR101431407B1/ko active Active
- 2006-03-29 SG SG10201703816SA patent/SG10201703816SA/en unknown
- 2006-03-29 MX MX2007014132A patent/MX2007014132A/es active IP Right Grant
- 2006-03-29 KR KR1020157019319A patent/KR101782236B1/ko active Active
- 2006-03-29 RU RU2007146462A patent/RU2448096C3/ru active
- 2006-03-29 PT PT06748863T patent/PT1893196E/pt unknown
- 2006-03-29 EP EP21193326.2A patent/EP3970721A1/en active Pending
- 2006-03-29 MX MX2019015200A patent/MX394667B/es unknown
- 2006-03-29 KR KR1020147029832A patent/KR101579701B1/ko active Active
- 2006-03-29 EP EP12193684A patent/EP2561871A1/en not_active Withdrawn
- 2006-03-29 MX MX2015003843A patent/MX346924B/es unknown
- 2006-03-29 KR KR1020147003529A patent/KR101515335B1/ko active Active
- 2006-03-29 CN CN2012100273781A patent/CN102584712A/zh active Pending
- 2006-03-29 JP JP2008511114A patent/JP4644737B2/ja active Active
- 2006-03-29 RS RS20120154A patent/RS52274B2/sr unknown
- 2006-03-29 KR KR1020247032344A patent/KR20240148945A/ko active Pending
- 2006-03-29 ME MEP-2012-154A patent/ME01992B/me unknown
- 2006-03-29 WO PCT/US2006/011417 patent/WO2006124118A1/en not_active Ceased
- 2006-03-29 CA CA2608436A patent/CA2608436C/en active Active
- 2006-03-29 KR KR1020127019589A patent/KR101332924B1/ko active Active
- 2006-03-29 AU AU2006248109A patent/AU2006248109B2/en active Active
- 2006-03-29 EP EP06748863.5A patent/EP1893196B2/en active Active
- 2006-03-29 EP EP11184401.5A patent/EP2444085B1/en not_active Revoked
- 2006-03-29 KR KR1020217035915A patent/KR102481886B1/ko active Active
- 2006-03-29 KR KR1020077029188A patent/KR101169832B1/ko active Active
- 2006-03-29 BR BRPI0610359A patent/BRPI0610359B8/pt active IP Right Grant
- 2006-03-29 CN CN2006800255451A patent/CN101222922B/zh active Active
- 2006-03-29 SI SI200631309T patent/SI1893196T2/sl unknown
- 2006-03-29 ES ES11184401.5T patent/ES2535179T3/es active Active
- 2006-03-29 CN CN202510689609.2A patent/CN120682155A/zh active Pending
- 2006-03-29 PT PT111844015T patent/PT2444085E/pt unknown
- 2006-03-29 DK DK11184401T patent/DK2444085T3/en active
- 2006-03-29 PL PL06748863T patent/PL1893196T5/pl unknown
- 2006-03-29 KR KR1020117007291A patent/KR101332889B1/ko active Active
- 2006-03-29 CN CN201510296329.1A patent/CN105037273B/zh active Active
- 2006-03-29 KR KR1020227045048A patent/KR102713358B1/ko active Active
- 2006-03-29 NZ NZ591119A patent/NZ591119A/xx unknown
- 2006-03-29 NZ NZ710355A patent/NZ710355A/en unknown
- 2006-03-29 CN CN201910163070.1A patent/CN110003114B/zh active Active
- 2006-03-29 RS RS20150269A patent/RS53967B1/sr unknown
- 2006-03-29 NZ NZ564223A patent/NZ564223A/en unknown
- 2006-03-29 PL PL11184401T patent/PL2444085T3/pl unknown
- 2006-03-29 KR KR1020197025316A patent/KR102324567B1/ko active Active
- 2006-03-29 CN CN202211664795.7A patent/CN116003328A/zh active Pending
- 2006-03-29 DK DK06748863.5T patent/DK1893196T4/en active
- 2006-03-29 ES ES06748863.5T patent/ES2378778T5/es active Active
- 2006-03-29 HR HRP20120323TT patent/HRP20120323T4/hr unknown
- 2006-03-29 SI SI200631926T patent/SI2444085T1/sl unknown
- 2006-03-29 KR KR1020177025842A patent/KR102020721B1/ko active Active
-
2007
- 2007-11-12 IL IL187328A patent/IL187328A/en active Protection Beyond IP Right Term
- 2007-11-12 MX MX2022009759A patent/MX2022009759A/es unknown
- 2007-12-12 NO NO20076401A patent/NO339997B1/no active Protection Beyond IP Right Term
- 2007-12-13 ZA ZA2007/10870A patent/ZA200710870B/en unknown
-
2010
- 2010-10-22 JP JP2010237937A patent/JP5138753B2/ja active Active
-
2011
- 2011-12-23 RU RU2011152891A patent/RU2638833C2/ru active
-
2012
- 2012-03-12 ZA ZA2012/01793A patent/ZA201201793B/en unknown
- 2012-04-18 CY CY20121100367T patent/CY1112798T1/el unknown
- 2012-07-30 JP JP2012168905A patent/JP2012211190A/ja not_active Withdrawn
- 2012-07-30 JP JP2012168904A patent/JP5150780B2/ja active Active
-
2013
- 2013-12-16 CY CY2013047C patent/CY2013047I2/el unknown
- 2013-12-17 LU LU92338C patent/LU92338I2/xx unknown
- 2013-12-17 HU HUS1300076C patent/HUS1300076I1/hu unknown
- 2013-12-18 BE BE2013C074C patent/BE2013C074I2/fr unknown
-
2015
- 2015-03-02 JP JP2015039980A patent/JP6013535B2/ja active Active
- 2015-04-21 HR HRP20150437TT patent/HRP20150437T1/hr unknown
-
2016
- 2016-01-28 IL IL243812A patent/IL243812A0/en unknown
- 2016-05-05 HK HK16105142.8A patent/HK1217103A1/zh unknown
- 2016-07-28 JP JP2016148183A patent/JP2016183200A/ja not_active Withdrawn
- 2016-12-15 NO NO20161996A patent/NO342490B1/no unknown
-
2017
- 2017-05-04 NO NO2017019C patent/NO2017019I2/no unknown
- 2017-12-05 RU RU2017142159A patent/RU2017142159A/ru unknown
-
2018
- 2018-02-13 NO NO20180225A patent/NO20180225A1/no unknown
- 2018-03-06 JP JP2018039424A patent/JP2018100292A/ja not_active Withdrawn
- 2018-04-23 IL IL258880A patent/IL258880A/en unknown
-
2019
- 2019-07-22 JP JP2019134558A patent/JP2019218352A/ja active Pending
-
2020
- 2020-11-11 JP JP2020187901A patent/JP2021035970A/ja not_active Withdrawn
-
2022
- 2022-04-25 JP JP2022071531A patent/JP2022101657A/ja active Pending
-
2023
- 2023-03-17 JP JP2023043191A patent/JP2023075313A/ja active Pending
-
2024
- 2024-07-19 JP JP2024115820A patent/JP2024153705A/ja active Pending
-
2025
- 2025-08-13 JP JP2025134786A patent/JP2025166151A/ja active Pending
- 2025-09-21 IL IL323480A patent/IL323480A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011068653A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| JP2012092149A5 (enExample) | ||
| JP2014516942A5 (enExample) | ||
| JP2009102342A5 (enExample) | ||
| IL314360B2 (en) | Method for the synthesis of thyroid hormone analogs and their polymorphs | |
| JP2013511507A5 (enExample) | ||
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| JP2016185995A5 (enExample) | ||
| FI3435996T3 (fi) | Elafibranori käytettäväksi primaarisen biliaarisen kolangiitin hoidossa | |
| PH12015502134A1 (en) | Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration | |
| JP2013518107A5 (enExample) | ||
| JP2014532704A5 (enExample) | ||
| JP2006515883A5 (enExample) | ||
| JP2014526503A5 (enExample) | ||
| JP2020505423A5 (enExample) | ||
| JP2014518266A5 (enExample) | ||
| HRP20201316T1 (hr) | Novi modulatori receptora sfingozin-fosfata | |
| JP2015529234A5 (enExample) | ||
| ME02474B (me) | Terapijski režimi | |
| TW201513864A (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JP2009539994A5 (enExample) | ||
| JP2016508996A5 (enExample) | ||
| JP2011500805A5 (enExample) | ||
| RU2015113031A (ru) | Использование 3-n-бутил изоиндолин кетонов при приготовлении лекарственных средств для профилактики и лечения церебрального инфаркта |